Mersana Therapeutics Announces Strategic Priorities and

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2022
19
Mersana Therapeutics Announces Strategic Priorities and Goals for 2019 and Beyond

Company to Focus its Resources on Advancing XMT-1536, its First-in-Class ADC Candidate Targeting NaPi2b, Showing Encouraging Early Signs of Efficacy

Dose Selection and Initiation of XMT-1536 Expansion Cohorts on Track for First Half 2019

XMT-1522 Development Discontinued Following Strategic Evaluation

CAMBRIDGE, Mass., Jan. 04, 2019 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc., (NASDAQ: MRSN ) a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) targeting cancers in areas of high unmet need, today announced that after a strategic evaluation the Company will prioritize its resources to focus on the advancement of XMT-1536, a first-in-class ADC candidate targeting NaPi2b. As a result, Mersana and its partner, Takeda, plan to terminate the co-development collaboration for XMT-1522. Mersana will work with investigators to ensure that patients benefitting from XMT-1522 will continue to have access to the therapy as needed. 

“While still in early clinical development, we are encouraged with the safety, tolerability, and activity of XMT-1536 as well as the pace at which the current study is advancing. For this reason, we have decided to focus our resources on advancing XMT-1536, our first-in-class ADC candidate targeting NaPi2b, a clinically validated ADC target broadly expressed in ovarian and non-small cell lung cancer (NSCLC) adenocarcinoma, for which there remains a significant unmet medical need,” said Anna Protopapas, President and CEO, Mersana Therapeutics. “We have made the difficult decision to terminate the further development of XMT-1522 despite a favorable emerging profile of efficacy and tolerability due to the competitive environment for HER2-targeted therapies.”

“Looking forward, we’re very enthusiastic about our clinical progress with XMT-1536 and the expansion of our clinical pipeline,” said Dirk Huebner, M.D., Chief Medical Officer, Mersana Therapeutics. “On behalf of the Company and our partner Takeda we want to thank the patients and their families for their participation in the study, as well as the investigators and our team for their diligent work on the clinical development of XMT-1522. We are committed to leveraging our proprietary ADC platforms to generate a differentiated pipeline of ADCs.”

Update on XMT-1536

  • XMT-1536 is a first-in-class ADC against a clinically validated target. Ovarian and non-small cell lung cancer (NSCLC) adenocarcinoma express NaPi2b and remain areas of significant unmet need. XMT-1536 has the potential to play a significant role in the treatment of these diseases.
  • The data to date from the ongoing XMT-1536 dose escalation study indicate that the trial has reached clinically relevant dose levels but has not yet reached a maximum tolerated dose. The once-every-three-week regimen has been fully explored.  The once-every-four-week schedule is currently being evaluated.  The 20 mg/m2 dose cohort has been shown to be well tolerated and the 30 mg/m2 is currently being evaluated.
  • As of December 31, 2018, the dose escalation study of XMT-1536, in multiple tumor types, includes eight heavily pretreated and evaluable ovarian cancer patients treated at clinically relevant doses. These patients are unselected for NaPi2b expression and had 3 to 11 (median 6) prior regimens in the platinum resistant or refractory setting. Of these eight patients, two achieved a partial response and the remaining six achieved stable disease. The higher dose levels currently being evaluated, as well as additional patient enrollment, provide the opportunity to further define and optimize the profile of XMT-1536.

Mersana Therapeutics 2019 Corporate Goals

XMT-1536

  • The Company expects to select a dose for use in its Phase 1 expansion studies and to initiate enrollment of patients in the expansion cohorts in the first half of 2019. The expansion cohorts will focus on platinum-resistant ovarian cancer and NSCLC adenocarcinoma. The Company also plans to utilize its proprietary and validated immunohistochemistry assay to retrospectively determine NaPi2b expression to determine whether a companion diagnostic would facilitate the clinical development of XMT-1536.
  • The Company plans to report Phase 1 dose escalation data in the first half of 2019.

Pipeline Expansion

  • The Company expects to disclose its next clinical candidate in the second half of 2019 and is targeting the filing of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) in the first half of 2020.

Research and Discovery

  • Mersana continues to build a pipeline of promising ADCs across a variety of tumor types with significant unmet need, leveraging its three proprietary ADC platforms (Dolaflexin, Dolasynthen, and Alkymer). 
  • The Company is applying its expertise in ADCs to optimize and validate Immunosynthen, a new platform designed to allow systemic delivery of a potent immunostimulatory molecule to provide optimal efficacy and tolerability.
  • Mersana plans to disclose the progress of these research and discovery efforts at scientific meetings throughout the year.

Corporate Developments

  • The Company is proactively evaluating the potential for strategic collaborations that maximize the value of each of its pipeline candidates and platforms.
  • Mersana is focused on the continued recruitment and retention of top talent, while maintaining a culture of scientific excellence, focused execution, and patient needs.

Upcoming Events

  • The Company will provide further details during its presentation at the 37 th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 9, 2019 at 3:00 pm PT.

About Mersana Therapeutics Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop highly targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefit to patients. Mersana’s lead product candidate, XMT-1536, is in a Phase 1 clinical trial in patients with tumors expressing NaPi2b, including ovarian cancer, NSCLC, and other cancers. In addition, multiple partners are using Mersana’s platform to advance their ADC pipelines.

Forward-Looking Statements This press release contains “forward-looking” statements within the meaning of federal securities laws.  These forward-looking statements are not statements of historical facts and are based on management’s beliefs and assumptions and on information currently available to management. Forward-looking statements include information concerning the Company’s business strategy and the design, progression and timing of its clinical trials. Forward-looking statements generally can be identified by terms such as “anticipates,” “believes,” “could,” “seeks,” “estimates,” “intends,” “may,” “plans,” “potential,” “predicts,” “projects,” “should,” “will,” “would” or similar expressions and the negatives of those terms. Forward-looking statements represent management’s beliefs and assumptions only as of the date of this press release. The Company’s operations involve risks and uncertainties, many of which are outside its control, and any one of which, or combination of which, could materially affect its results of operations and whether the forward-looking statements ultimately prove to be correct.  Factors that may materially affect the Company’s results of operations and whether these forward-looking statements prove to be correct include, among other things, that preclinical testing may not be predictive of the results or success of ongoing or later preclinical or clinical trials, that the development of the Company’s product candidates and new platforms will take longer and/or cost more than planned and that the identification of new product candidates will take longer than planned, as well as those listed in the Company’s Annual Report on Form 10-K filed on March 28, 2018, with the Securities and Exchange Commission (“SEC”), the Company’s Quarterly Report on Form 10-Q filed with the SEC on November 13, 2018, and subsequent SEC filings. Except as required by law, the Company assumes no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.

Contacts:

Investor Contact Sarah Carmody, 617-844-8577 scarmody@mersana.com

Media Contact Paul Kidwell, 617-680-1088 pkidwell@mersana.com

 

Scroll down for more posts ▼

Top 10 Most Recent News Articles

AI Governance Is Becoming Enterprise Infrastructure

Updated Category News Views 69

Governance Has Finally Reached the Engine Room Enterprise AI is no longer a shiny pilot parked in some innovation lab; it is creeping into business-critical work, and that changes the argument entirely. Frost & Sullivan’s latest analysis makes a sensible point that too many executives still resist: AI governance is becoming a strategic operating capability, not merely a...

Continue Reading
Fraud0-FouAnalytics Takes Aim at Legacy Ad Verification

Updated Category News Views 95

Digital ad measurement has spent years grading its own homework, and that little arrangement may finally be getting some daylight. fraud0 and FouAnalytics say their expanded partnership will give advertisers impression-level visibility into where ads actually rendered, whether apparent humans engaged with them, and where wasted Google Ads spend might be recoverable. The...

Continue Reading
Chicago Kertész Show Puts Photography's Quiet Giant First

Updated Category News Views 112

A fork, a plate, and a sharp eye can outlast plenty of louder art. Leica Gallery Chicago is putting that proposition on the wall with André Kertész: The Master, opening December 4, 2026 and running through January 17, 2027. More than thirty signature works is not a sprawling museum survey, and frankly that may be the point. Kertész did not need grand scale to make his...

Continue Reading
Pennsylvania Housing Finds Its October Holding Pattern

Updated Category News Views 108

Pennsylvania's October housing numbers have the uneasy stillness of a pond before somebody throws a rock. The statewide median sales price sat at $315,000, exactly where it was in September, while sales barely cleared 10,400 and available listings kept inching higher. Nothing in that mix screams boom or bust. Frankly, that is the point: a market can look calm on the...

Continue Reading
Mason Adds Nonprofit Expertise to Institutional Bench

Updated Category News Views 110

Endowment committees rarely need more noise; they need somebody who has actually sat through the uncomfortable votes. Mason Investment Advisory Services has hired Rebecca “Becky” Farnsworth, CFA, as a senior investment consultant, and this looks like a practical addition rather than the usual chest-thumping personnel announcement. Her stated focus will be...

Continue Reading
Faex Health Adds Ebola and H. pylori AI Screening Tools

Updated Category News Views 82

A smartphone pointed at a toilet is an awkward place to hunt for medical progress, yet Faex Health is making a serious attempt to turn that daily evidence into an early-warning tool. The company has added investigational pre-screening capabilities for Ebola virus disease and Helicobacter pylori, or H. pylori, bringing its internally validated panel to 18 gastrointestinal...

Continue Reading
Industrial Air Compressors: Fix, Rebuild, or Replace

Updated Category News Views 90

A compressor’s ugliest invoice is rarely the one from the service technician. It is the one nobody sees at first: a stalled production line, missed output, overtime, wasted electricity, and a maintenance crew chasing the same machine again next month. Pam Mahood of Waterloo, Iowa-based Compressed Air & Equipment Co. puts the decision where it belongs—not on the price...

Continue Reading
iHeart's 65% Plunge Brings a Fraud Probe Into Focus

Updated Category News Views 71

November 10 did not merely bruise iHeartMedia shareholders; it left the stock closing at $0.61 after a decline of more than 65%. That kind of move gets everybody’s attention, including plaintiffs’ lawyers, and Wolf Haldenstein Adler Freeman & Herz LLP has opened an investigation into potential securities fraud claims involving iHeartMedia, its officers, and its...

Continue Reading
ASA’s 2026 Grants Push Dermatology Into New Terrain

Updated Category News Views 80

Thirteen Small Bets With Serious Human Stakes Skin science rarely gets the splashy headlines, yet it touches a staggering number of people and carries some very stubborn unanswered questions. American Skin Association’s 2026 grant class puts 13 awards across skin cancer and dermatologic disease, with a noticeable willingness to follow newer clinical terrain rather than...

Continue Reading
Cash Flow Discipline Is Where Business Growth Gets Real

Updated Category News Views 73

A full order book can still leave a company gasping at payroll. That is the unglamorous point behind the Nov. 20, 2026, HelloNation piece featuring Kimberly Furrh of Furrh & Associates PC in Lawton, Oklahoma. Owners love to talk about sales because sales are visible, flattering and easy to celebrate. Cash is less theatrical. It is also the thing that keeps the lights on...

Continue Reading

Top 5 Most Recently Viewed Articles

An In-Depth Analysis of Qorvo's Current Short Interest Trends

Updated Category News Views 215

Understanding Qorvo's Short Interest Movement Qorvo Inc. (NASDAQ: QRVO) has been experiencing notable changes in its short interest, with a recent report indicating a decrease of 16.17%. This drop reflects a total of 5.20 million shares sold short, equating to about 7.67% of the total shares available for trading. Traders should note that, with the current trading volume,...

Continue Reading
Sev1Tech Secures $188M Contract with U.S. Space Force

Updated Category News Views 167

Sev1Tech Secures a Major Contract with the U.S. Space Force Sev1Tech has recently made headlines by being awarded a substantial contract valued at $188 million from the U.S. Space Force (USSF), specifically under the Space Systems Command (SSC). This contract involves expanding the support for an innovative and powerful network known as meshONE-T. This network is...

Continue Reading
Exploring Rigetti Computing's Growth and ETF Impact

Updated Category News Views 339

Understanding the Surge of Rigetti Computing Rigetti Computing Inc. (NASDAQ: RGTI) has seen an extraordinary performance recently, with its shares rising a staggering 100% year-to-date, and almost 3,900% over the past year. This impressive increase has attracted considerable investor interest, particularly from those focused on opportunities in the rapidly evolving...

Continue Reading
Kratos Defense Stock Climbs High: What Investors Should Know

Updated Category News Views 198

Kratos Defense Stock Reaches New Heights Kratos Defense (NASDAQ: KTOS) has recently achieved a remarkable milestone by hitting a 52-week high of $30.42. This achievement comes amid a strong defense market, marking a significant increase in the company's stock value with a one-year growth of 55.96%. Investors demonstrate growing confidence in Kratos, renowned for its...

Continue Reading
Precision Linear Actuators for Optical and Automation Needs

Updated Category News Views 143

High-Precision Micro-Positioning Solutions Available For those seeking reliability and accuracy in optical alignment, precision automation, and research applications, the latest offerings from PI deliver exceptional results. Introducing the L-220 Series Linear Actuators PI’s L-220 series linear actuators are designed for applications demanding sub-micrometer precision....

Continue Reading